Literature DB >> 25897040

Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy.

Hong-Mi Choi1, Kyung-Hee Kim2, Joo Myung Lee1, Yeonyee E Yoon1, Seung-Pyo Lee1, Eun-Ah Park3, Whal Lee3, Yong-Jin Kim1, Goo-Yeong Cho1, Dae-Won Sohn1, Hyung-Kwan Kim1.   

Abstract

OBJECTIVE: We hypothesised that, in hypertrophic cardiomyopathy (HCM), late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) is progressive and can be predicted by baseline CMR findings and HCM phenotype.
METHODS: In this single-centre cohort study, 71 patients with HCM (59±13 years; 48 men) were prospectively enrolled with clinical, echocardiographic and CMR data. Two consecutive CMR scans were performed with a time interval of 582±174 days. The LGE extent was quantified as a proportion of total LV myocardium (%LGE).
RESULTS: LGE was present in 65 patients (91.5%) at the first CMR (CMR-1). In all, LGE extent was significantly increased (p<0.001). A difference in %LGE between the two CMR scans was correlated with the initial %LGE (r=0.44, p<0.001). LGE progression, defined as >4% increase in LGE at the second CMR, was present in 19 patients with non-apical HCM (36.5%), but in only one apical HCM (5.3%). Also, LGE progression rate was significantly higher in non-apical (0.15%/month) versus apical HCM (0.025%/month) (p=0.001). On the multivariate model #1 including only clinical variables (age, history of paroxysmal atrial fibrillation, LV outflow tract obstruction on echocardiography, beta-blocker use, family history of sudden death, family history of HCM, syncope, non-sustained ventricular tachycardia, rate pressure product, and HCM phenotype), only apical HCM phenotype was associated with less LGE progression (p=0.038). On the multivariate model #2 including CMR variables additional to the model #1, %LGE at CMR-1 was the only determinant for LGE progression (p=0.007). When the analysis was limited to patients with preserved EF, results remained unchanged.
CONCLUSIONS: Myocardial fibrosis in HCM is a progressive phenomenon. Non-apical phenotype and a higher LGE extent at CMR-1 are both associated with greater LGE progression. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25897040     DOI: 10.1136/heartjnl-2014-306555

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  8 in total

1.  3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy.

Authors:  Liang Yin; Hai-Yan Xu; Sui-Sheng Zheng; Ying Zhu; Jiang-Xi Xiao; Wei Zhou; Si-Si Yu; Liang-Geng Gong
Journal:  Int J Cardiovasc Imaging       Date:  2017-06-13       Impact factor: 2.357

2.  Discrepancy Between Pathological Progression and Clinical Stability in a Young Patient With Hypertrophic Cardiomyopathy.

Authors:  Betty Raman; David Wen; Kenneth Chan; Hugh Watkins; Stefan Neubauer; Masliza Mahmod
Journal:  Circ Cardiovasc Imaging       Date:  2018-11       Impact factor: 7.792

3.  Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy.

Authors:  Anna Axelsson Raja; Hoshang Farhad; Anne Marie Valente; John-Paul Couce; John Lynn Jefferies; Henning Bundgaard; Kenneth Zahka; Harry Lever; Anne M Murphy; Euan Ashley; Sharlene M Day; Mark V Sherrid; Ling Shi; David A Bluemke; Charles E Canter; Steven D Colan; Carolyn Y Ho
Journal:  Circulation       Date:  2018-08-21       Impact factor: 29.690

4.  Sex-related differences in left ventricular remodeling and outcome after alcohol septal ablation in hypertrophic obstructive cardiomyopathy: insights from cardiovascular magnetic resonance imaging.

Authors:  You-Zhou Chen; Xing-Shan Zhao; Jian-Song Yuan; Yan Zhang; Wei Liu; Shu-Bin Qiao
Journal:  Biol Sex Differ       Date:  2022-07-07       Impact factor: 8.811

5.  Prognostic value of cardiovascular magnetic resonance imaging for life-threatening arrhythmia detected by implantable cardioverter-defibrillator in Japanese patients with hypertrophic cardiomyopathy.

Authors:  Yasuki Hen; Mayuko Tsugu-Yagawa; Nobuo Iguchi; Yuko Utanohara; Kaori Takada; Haruhiko Machida; Ayako Takara; Kunihiko Teraoka; Kanki Inoue; Itaru Takamisawa; Morimasa Takayama; Tsutomu Yoshikawa
Journal:  Heart Vessels       Date:  2017-08-01       Impact factor: 2.037

6.  Patterns of Left Ventricular Hypertrophy and Late Gadolinium Enhancement on Cardiac MRI in Patients with Hypertrophic Cardiomyopathy and their Prognostic Significance - An Experience from a South Asian Country.

Authors:  Fateh Ali Tipoo Sultan; Sheema Saadia
Journal:  J Clin Imaging Sci       Date:  2021-03-04

Review 7.  Major Clinical Issues in Hypertrophic Cardiomyopathy.

Authors:  Hyung-Kwan Kim; Sang Chol Lee; Hyun-Jung Lee; Jihoon Kim; Sung-A Chang; Yong-Jin Kim
Journal:  Korean Circ J       Date:  2022-08       Impact factor: 3.101

8.  Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications.

Authors:  Betty Raman; Rina Ariga; Marco Spartera; Sanjay Sivalokanathan; Kenneth Chan; Sairia Dass; Steffen E Petersen; Matthew J Daniels; Jane Francis; Robert Smillie; Adam J Lewandowski; Eric O Ohuma; Christopher Rodgers; Christopher M Kramer; Masliza Mahmod; Hugh Watkins; Stefan Neubauer
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2019-02-01       Impact factor: 6.875

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.